BGI Genomics Co., Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shenzhen Huada Gene Co., Ltd., as the founder of China's gene industry, adheres to the vision of "gene technology benefits humanity". Through more than 20 years of talent accumulation, scientific research accumulation, and industrial accumulation, it has built a marketing service network covering more than 100 countries and all provinces, cities, and autonomous regions in the world. It has become one of the few technology companies that covers the entire industry chain and application fields of this industry, based on advanced technology The fully equipped and leading multi omics output platform has become one of the few scientific and technological service providers and precision medical service operators worldwide. The company's main business is to provide research services and comprehensive solutions for precision medical testing to scientific research institutions, enterprises, medical institutions, social health organizations, etc. through multiple omics big data technology methods such as genetic testing, mass spectrometry testing, and bioinformatics analysis. Starting from promoting the progress of life science research, the application of life big data, and the improvement of global medical and health standards, BGI Gene is committed to accelerating technological innovation, reducing birth defects, strengthening tumor prevention and control, suppressing the harm of major diseases to humans, achieving precise cure of infections, and comprehensively supporting precision medicine based on research achievements in the field of genetics and the application of precise detection technology in people's health. The company is headquartered in Shenzhen, China, and has branches and medical laboratories in major cities in China such as Beijing, Tianjin, Wuhan, Shanghai, and Guangzhou. It also has overseas centers and core laboratories in Hong Kong, Europe, the Americas, Asia Pacific, and other regions, forming a network layout that covers the whole country and radiates globally. Its business covers more than 100 countries and regions worldwide, including more than 2000 scientific research institutions and more than 2300 medical institutions in China, Among them, there are over 500 tertiary hospitals; More than 3000 overseas medical and research institutions have cooperated in Europe, the Americas, Asia Pacific, and other regions, and have established cooperative relationships with health regulatory agencies in over 30 countries and regions. |
| Headquarter | Shenzhen |
| Establish Date | 7/9/2010 |
| Listed Code | 300676.SZ |
| Listed Date | 7/14/2017 |
| Chairman | Wang Jian. |
| CEO | Zhao Lijian. |
| Website | www.bgi.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
